- Home
- BY vs GYRE Comparison
BY vs GYRE Comparison
Compare BY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- GYRE
- Stock Information
- Founded
- BY 1914
- GYRE 2002
- Country
- BY United States
- GYRE United States
- Employees
- BY N/A
- GYRE N/A
- Industry
- BY Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- GYRE Health Care
- Exchange
- BY Nasdaq
- GYRE Nasdaq
- Market Cap
- BY 1.1B
- GYRE 897.1M
- IPO Year
- BY 2017
- GYRE N/A
- Fundamental
- Price
- BY $26.24
- GYRE $9.53
- Analyst Decision
- BY Hold
- GYRE
- Analyst Count
- BY 3
- GYRE 0
- Target Price
- BY $33.67
- GYRE N/A
- AVG Volume (30 Days)
- BY 161.2K
- GYRE 105.9K
- Earning Date
- BY 04-24-2025
- GYRE 05-09-2025
- Dividend Yield
- BY 1.53%
- GYRE N/A
- EPS Growth
- BY N/A
- GYRE N/A
- EPS
- BY 2.69
- GYRE 0.04
- Revenue
- BY $379,386,000.00
- GYRE $100,643,000.00
- Revenue This Year
- BY $14.38
- GYRE $22.01
- Revenue Next Year
- BY $5.04
- GYRE $88.14
- P/E Ratio
- BY $9.80
- GYRE $213.36
- Revenue Growth
- BY 3.48
- GYRE N/A
- 52 Week Low
- BY $21.96
- GYRE $6.11
- 52 Week High
- BY $32.89
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- BY 56.50
- GYRE 55.67
- Support Level
- BY $25.57
- GYRE $8.51
- Resistance Level
- BY $26.61
- GYRE $9.98
- Average True Range (ATR)
- BY 0.60
- GYRE 0.61
- MACD
- BY 0.19
- GYRE 0.10
- Stochastic Oscillator
- BY 85.35
- GYRE 73.84
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.